- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03958617
Thalamic Deep Brain Stimulation for Tourette Syndrome
May 21, 2019 updated by: Jens Kuhn, University of Cologne
Thalamic Deep Brain Stimulation for Tourette's Syndrome: a Pragmatic Trial With Brief Randomized, Double-blinded Sham Controlled Sequences
In this single-center trial, we aim to include 8 patients with severe and medically refractory Tourette's syndrome.
All patients undergo deep brain stimulation surgery with two electrodes located in the centromedian-parafascicular complex.
Tic severity and secondary outcome measurements are assessed six and twelve months after surgery.
Additionally, a short randomized, double-blinded sham controlled crossover sequence of 24 to 48 hours in either active or sham stimulation is implemented after both 6 and 12 months assesments.
Subjects and clinicians are blinded to treatment allocation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cologne, Germany, 50924
- University of Cologne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Das Tourette-Syndrom (ICD-10: F 95.2; DSM IV: 307.23) als Hauptdiagnose. Bei dem Patienten ist aufgrund einer chronischen, schwergradigen und therapieresistenten Verlaufsform des TS eine Behandlung mittels THS thalamischer Strukturen im Sinne einer ultima ratio vorgesehen.
- Alter des Patienten 18 bis 65 Jahre
- Sicher im Verstehen der deutschen Sprache
- Unterzeichnete Einverständniserklärung
Exclusion Criteria:
- Klinisch manifeste Psychose
- Schwangerschaft und Stillzeit
- Unterbringung nach PsychKG
- Kontraindikationen einer MRT-Untersuchung wie z. B. implantierter Herzschrittmacher / Defibrillator
- Neoplastische neurologische Erkrankungen
- Kontraindikationen einer stereotaktischen Operation, wie z. B.: erhöhte Blutungsneigung, cerebrovaskuläre Erkrankungen (z. B. arteriovenöse Malformationen, Aneurysmata, systemische Gefäßerkrankungen, die auf das Cerebrum übergreifen).
- Teilnahme an einer anderen klinischen Studie
- Hirnassoziierte Kriterien, die eine OP ausschließen (Gefäßanomalien, große arteriovenöse Malformationen, Hirnmetastasen, Neoplasien des ZNS (Ausnahme asymptomatisches inzidentielles Meningeom))
- Antikoagulationtherapie, die in der perioperativen Phase nicht ausgesetzt werden kann
- OP am Gehirn in der Anamnese, die mit der Platzierung/Funktion des MP interferieren
- Med. Gegebenheiten, die mit der Studienprozedur interferieren oder Evaluation der Studienparameter beeinträchtigen inkl. Erkrankungen im terminalen Stadium (Lebenserwartung < 12 Monate)
- Akute Suizidalität
- Abhängigkeit von Alkohol oder Drogen (exklusive Cannabis, da es von schwer betroffenen Patienten teilweise zur Ticreduktion im Sinne einer Selbstmedikation eingesetzt wird sowie exklusive Opioide und Benzodiazepine, wenn diese initial zur Ticreduktion im Sinne einer Selbstmedikation eingesetzt wurden)
- Klinisch relevante internistische oder neurologische Erkrankungen
- Intelligenzminderung
- Alle aktiv implantierten Medizinprodukte
- Schweres Schädel-Hirn-Trauma in der Anamnese
- Metallimplantate im Kopfbereich ( Bsp. Aneurysmaclips)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: On condition
Ongoing thalamic deep brain stimulation
|
|
Sham Comparator: Off condition
Switched off thalamic deep brain stimulation, sham stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Yale Global Tic Severity Scale (YGTSS)
Time Frame: Change in the YGTSS Scale from Baseline to 6 and 12 months
|
Motor tic subscore range 0-25 Vocal tic scubscore range 0-25 Impairment range0-50 Total Score (Vocal tic score + Motor tic score + Impairment) range 0-100 Higher Scores indicate higher tic severity, thus worse outcome |
Change in the YGTSS Scale from Baseline to 6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rush video rating scale (MRVRS)
Time Frame: Change in the MRVRS Scale from Baseline to 6 and 12 months
|
Range 0-20 Higher Scores indicate higher tic severity, thus worse outcome |
Change in the MRVRS Scale from Baseline to 6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jens Kuhn, MD, University Hospital of Cologne
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2014
Primary Completion (Actual)
February 28, 2019
Study Completion (Actual)
March 31, 2019
Study Registration Dates
First Submitted
June 26, 2017
First Submitted That Met QC Criteria
May 19, 2019
First Posted (Actual)
May 22, 2019
Study Record Updates
Last Update Posted (Actual)
May 23, 2019
Last Update Submitted That Met QC Criteria
May 21, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Disease
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Neurodevelopmental Disorders
- Tic Disorders
- Syndrome
- Tourette Syndrome
Other Study ID Numbers
- 1648
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tourette Syndrome
-
Children's Hospital Medical Center, CincinnatiTourette Association of AmericaRecruitingTourette Syndrome | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tourette Syndrome, Modifier ofUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ministry of Health, ItalyCompletedTourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette SyndromeItaly
-
Tasly Pharmaceuticals, Inc.Not yet recruitingTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States
-
Emalex Biosciences Inc.CompletedTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States, Poland, France, Canada, Germany
-
Vanderbilt University Medical CenterCompletedTourette Syndrome | Tourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States
-
Johns Hopkins UniversityCompletedTourette Syndrome in Children | Tourette Syndrome in Adolescence | Habit Reversal Training | TicUnited States
-
Tel Aviv Medical CenterUnknownTourette Syndrome in Children | Tourette Syndrome in Adolescence | Chronic Tic DisorderIsrael
-
University of UtahRecruitingClinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder (PTD)Tourette Syndrome | Tic Disorders | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Vocal Tic | Motor Tic | Tics/TremorUnited States
-
Wake Forest University Health SciencesUniversity of Rochester; Tourette Association of AmericaRecruitingTourette Syndrome | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tic Disorder, ChildhoodUnited States
-
University of MinnesotaCompletedTourette Syndrome | Tic Disorders | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tic Disorder, Childhood | Tic, MotorUnited States
Clinical Trials on Bilateral Deep brain stimulation of the thalamus, Medtronic Device
-
Jorge Gonzalez-MartinezNot yet recruitingCardiovascular Diseases | Stroke | Central Nervous System Diseases | Nervous System Diseases | Brain DiseaseUnited States
-
Chen LingPrince of Wales Hospital, Shatin, Hong Kong; Shenzhen Second People's HospitalCompletedParkinson DiseaseChina
-
Qilu Hospital of Shandong UniversityRecruiting
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
The Hospital for Sick ChildrenCompletedSelf-Injurious Behavior | Autism Spectrum DisorderCanada
-
Jonathan JagidUnited States Department of DefenseCompletedPain | Autonomic DysreflexiaUnited States
-
Qilu Hospital of Shandong UniversityRecruiting
-
George Washington UniversityCompletedMesial Temporal Lobe EpilepsyUnited States
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS); MedtronicActive, not recruiting
-
Hospital San Carlos, MadridCompletedObsessive-Compulsive Disorder